Full-Time

Care Pathway Lead

Cardiology

Posted on 11/18/2025

Viz.ai

Viz.ai

201-500 employees

AI-driven real-time imaging analysis and alerts

Compensation Overview

$156k - $223k/yr

+ Stock Options

Remote in USA

Remote

Remote in the United States; travel up to 50% may be required.

Category
Business & Strategy (1)
Requirements
  • 15+ years’ experience leading high priority initiatives focused on program delivery to improve areas of clinical care. Experience in areas including medical device, product, clinical, clinical research or biotech development in an industry environment with demonstrable experience managing teams toward success.
  • Strong understanding of Cardiology, current clinical, operational, and economic challenges with ability to innovate in clinical development, program design.
  • Ability to influence behavior change and adoption of new care pathways through engagement of healthcare providers, care teams, life science customers and presentation of relevant evidence to decision-makers.
  • Interpret, discuss and present program level data to make continuous improvement in product, user experience, user engagement and adoption to drive value demonstration.
  • Awareness of variations in care delivery models, clinical trial design, regulatory/clinical development process and/or identifying cross functional team support where needed.
  • AI native: you use AI as much as you can both personally and professionally
  • Strong written and verbal communication skills, including comfort level with senior management and executive level presentations. Demonstrated ability to establish strong partnership with key stakeholders
  • Proven track record leading across cross-functional teams and ability to influence without direct authority.
  • Strong interpersonal skills and credibility to achieve goals, drive change, and improve collaboration.
  • Ability to travel 30% 50% of the time
Responsibilities
  • Report directly to the Sr. Director of Clinical
  • Leading the Care Pathway (CP) Program for Cardiology
  • You are the accountable CP leader and expert, responsible for the overall success of the CP that delights the life science customer and delivers value to healthcare providers.
  • You have the final say on what is best for the CP and are accountable for ensuring it gets done, advocating for your CP when execution requires shared resources – this means you are involved in all key activities
  • You escalate issues as needed and drive and provide reporting and visibility within Viz to the sponsoring executive
  • You quarterback across CP workstreams, driving structure, cadences, and accountability
  • Design the operations for, lead and drive collaboration for a cross functional team for the overall Care Pathway Program.
  • Serve as the voice of the healthcare provider and clinical teams as a trusted partner to build care pathways that close existing gaps.
  • Maintain strong relationships with Life Science and hospital customers, internal cross-functional teams, and clinical champions at the Care Pathway Sites.
  • Serve as the Cardiology Care Pathway expert both internally and externally; lead interactions with stakeholders (e.g., life science partners, key opinion leaders, advisory boards, patient advocacy groups), internal stakeholders (e.g., Account Executive, New Markets, Product Management, Clinical, Global Medical Affairs, Marketing, Health Economics).
  • Lead communication of program/project status, changes and risks horizontally and vertically in a proactive, transparent and timely manner in relation to meeting OKRs and SOW specific milestones.
  • Utilize strong business acumen to manage cost of overall project against the value, identify opportunities to reduce costs, increase efficiencies and increase ROI.
  • Ultimately defined as profitable contract expansion with the life sciences partner.
Desired Qualifications
  • You are passionate about clinical AI-adoption to further healthcare delivery.
  • You have an entrepreneurial drive as well as a passion for engaging healthcare providers to support workflow optimization through delightful product experience
  • You have a deep understanding of clinical workflows in Cardiology, and management of patients in specified therapeutic area and a good sense of how to improve workflows to benefit patients
  • You have a strong ability to influence, manage behavior change, and are passionate about driving outcomes and focus on moving multiple teams towards the objective
  • You enjoy leading cross functional teams to facilitate care pathway specific knowledge transfer to Commercial, Marketing, and Product Teams and know how to get stuff done at Viz.
  • AI Native: You treat AI as a core part of your workflow, using tools like ChatGPT to enhance productivity and output

Viz.ai provides an AI-powered care coordination platform for healthcare that analyzes medical images in real time to detect time-sensitive conditions like stroke, pulmonary embolism, aortic dissection, and aneurysm from CT scans, EKGs, and echocardiograms. When the system detects a potential issue, it automatically notifies the relevant specialists through a HIPAA-compliant mobile app to speed collaboration and treatment. It operates as a subscription-based SaaS for hospitals and health systems, with adoption across thousands of hospitals in the U.S. and Europe, and partnerships with pharma and medical device companies to accelerate therapy access and support clinical trials. The goal is to shorten time-to-treatment by accelerating diagnosis and care coordination across the care team, using FDA-cleared AI algorithms and a broad hospital network to support clinical decision-making.

Company Size

201-500

Company Stage

Growth Equity (Venture Capital)

Total Funding

$291.5M

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • 2,000 hospitals create strong distribution and evidence-generation leverage.
  • Pulmonary, hemorrhage, and rural-health expansions widen use cases beyond stroke.
  • Life-sciences partnerships and CMS reimbursement strengthen monetization across care and trials.

What critics are saying

  • Epic and other EHR vendors can bundle similar workflows into native products.
  • FDA post-market scrutiny creates launch delays if algorithm performance drifts.
  • Hospital consolidation compresses pricing and forces annual contract renegotiations.

What makes Viz.ai unique

  • Viz.ai combines 50-plus FDA-cleared algorithms with workflow coordination.
  • Viz.ai One integrates EHR, PACS, and mobile communication across specialties.
  • Viz Agent Studio lets hospitals build custom care pathways using natural language.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Viz.ai who can refer or advise you

Benefits

Health, dental, & vision insurance

401K retirement plan

Generous vacation time

Paid parental leave

Monthly wellness days

Professional development stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Daily Corinthian
Apr 9th, 2026
Viz.ai ranked no. 1 for second consecutive year in 2026 Black Book survey of independent AI clinical decision support solutions.

Viz.ai ranked no. 1 for second consecutive year in 2026 Black Book survey of independent AI clinical decision support solutions. * ACCESS Newswire * Apr 9, 2026 * 0 Black Book report finds the market is shifting from stand-alone alerts to enterprise-scale AI platforms that combine clinically credible detection, workflow orchestration, mobile care coordination, and measurable operational impact NEW YORK CITY,... * ACCESS Newswire Black Book report finds the market is shifting from stand-alone alerts to enterprise-scale AI platforms that combine clinically credible detection, workflow orchestration, mobile care coordination, and measurable operational impact NEW YORK CITY,... * ACCESS Newswire Newsletters.

ACCESS Newswire Inc.
Apr 9th, 2026
About the 2026 Black Book AI Clinical Decision Support Survey

Black Book report finds the market is shifting from stand-alone alerts to enterprise-scale AI platforms that combine clinically credible detection, workflow orchestration, mobile care coordination, and measurable operational impact NEW YORK CITY, NY / ACCESS Newswire / April 9, 2026 / Black Book Research today announced that Viz.ai has been ranked No. 1 for the second consecutive year in its 2026 survey of independent AI Clinical Decision Support solutions, based on direct input from healthcare users across hospitals, health systems, medical groups, and clinical service-line operations. The annual report evaluates independent, non-EHR-embedded or native clinical AI and care coordination platforms on eighteen performance indicators tied to real-world usability, workflow fit, speed-to-intervention, care team response, analytics, governance, and long-term enterprise value. The Q2 2026 findings show that healthcare organizations are no longer judging clinical AI vendors on algorithm claims alone. Instead, users are increasingly rewarding platforms that can identify clinically meaningful signals, route the right teams in real time, support closed-loop follow-up, integrate into existing imaging and enterprise workflows, and demonstrate measurable improvement in response performance across time-sensitive care pathways. Black Book's analysis found that the market has moved decisively beyond isolated alerting toward operational AI decision layers that connect detection, communication, escalation, and documented action. Viz.ai's top ranking reflects strong user performance across the categories most associated with enterprise adoption and renewal confidence. Respondents rated the company especially highly for speed-to-alert, workflow orchestration, mobile team coordination, integration depth, specialty expansion, and its ability to translate AI-driven detection into organized clinical action. Users also cited Viz.ai's strength in supporting multidisciplinary teams with shared context, accelerating time-sensitive intervention, and extending beyond single-use-case deployment into broader service-line enablement. "The second consecutive No. 1 ranking for Viz.ai is significant not because of brand visibility, but because it reflects repeated validation from actual users working in live care environments," said Doug Brown, Founder of Black Book Research. "Our 2026 report shows a clear trend: the highest-performing independent clinical AI vendors are those that move beyond detection and function as operational platforms for rapid decision support, coordinated response, and measurable care pathway improvement. Viz.ai distinguished itself again this year by consistently earning strong marks for workflow execution, speed-to-treatment enablement, cross-team coordination, and enterprise scalability." According to Black Book's report, top-tier vendors were differentiated by a common set of performance characteristics. These included high-signal clinical detection with credible prioritization, closed-loop routing that reduces handoff failures, integration across EHR, PACS, mobile, messaging, and specialty workflows, and the ability to scale across service lines without requiring fragmented governance models. The report also found that renewal confidence was most closely linked to measurable time-to-treatment analytics, explainability and evidence visibility, strong implementation support, and product roadmaps that extend from point detection to enterprise pathway orchestration. Viz.ai's leading placement reflects how users increasingly define value in this category. Rather than viewing clinical AI as a narrow diagnostic adjunct, respondents described greater trust in vendors that can operationalize urgent findings, support rapid consultation and escalation, and document next-step accountability across complex care teams. In that context, Viz.ai was repeatedly recognized as a platform capable of aligning disease detection, communication, and workflow execution in a way that supports both front-line clinicians and broader health system performance objectives. Black Book emphasized that the 2026 rankings were developed through a vendor-agnostic, non-compensated, non-commissioned research process. The study gave special attention to the experiences of users directly engaged in patient care, operational execution, and day-to-day clinical workflow, rather than relying primarily on CIOs, purchasing officers, or vendor-sponsored reference accounts. That methodology was designed to capture how these platforms perform in practice, where clinical trust, responsiveness, implementation discipline, and workflow adoption determine real value. The 2026 Black Book report concludes that the independent clinical AI market is entering a more mature phase, with buyers increasingly prioritizing enterprise readiness, workflow intelligence, governance transparency, and measurable results over narrowly framed model performance claims. Viz.ai's repeat No. 1 ranking places it at the center of that shift, as users pointed to its ability to combine AI-enabled detection with care coordination, response acceleration, and scalable decision-support infrastructure across high-acuity clinical settings. About the 2026 Black Book AI Clinical Decision Support survey. The 2026 Black Book survey evaluated independent AI Clinical Decision Support and care coordination vendors serving healthcare providers across the United States. Eighteen key performance indicators were used in the rankings, including clinical detection quality, speed-to-alert, workflow orchestration, integration, scalability, explainability, analytics, implementation, customer support, governance, and long-term enterprise value. The study focused specifically on solutions that are independent of core EHR-native functionality and assessed performance through the perspective of real users in operational and clinical environments. Black Book report subscribers can download the full report or upon request. About Black Book Research Black Book Research is an independent healthcare market research and public opinion research organization specializing in unbiased evaluations of healthcare technology, outsourcing, managed services, digital health, and revenue cycle performance. Black Book surveys are vendor agnostic, not vendor compensated, and not vendor commissioned. Its research methodology emphasizes direct user experience and operational performance to provide healthcare leaders with transparent market intelligence grounded in real-world use.

Viz.ai
Apr 9th, 2026
Viz.ai earns back-to-back No. 1 ranking in Black Book survey of AI Clinical Decision Support solutions.

Viz.ai earns back-to-back No. 1 ranking in Black Book survey of AI Clinical Decision Support solutions. Independent, user-validated findings in 2026 report reinforces viz.ai's growing leadership over a competitive field as healthcare shifts to clinical AI infrastructure. San Francisco, CA - April 9, 2026 - Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has been ranked No. 1 in the Black Book Research survey of AI Clinical Decision Support solutions for the second consecutive year. Based on direct feedback from 1,237 healthcare professionals, including clinicians, administrators, and operational leaders across hospitals, health systems, and medical groups, the annual Black Book survey evaluates vendors on enterprise scalability, real-world performance across workflow integration, speed to intervention, care coordination, and analytics. Viz.ai ranked top overall, and No. 1 in the majority (13 of 18) of the categories, further reinforcing Viz.ai's significant leadership position across the category. Clinical AI has emerged as a core agentic infrastructure layer as health systems face growing pressure to improve outcomes while managing operational complexity. Healthcare organizations are moving beyond standalone AI tools and prioritizing enterprise platforms that operationalize insights by connecting detection, communication, and coordinated action across care teams. This is Viz.ai's second consecutive No.1 ranking, positioning the company at the forefront of agentic AI in healthcare. Respondents highlighted Viz.ai's ability to scale across the enterprise, and highlighted Viz.ai's strength in enabling coordinated, multidisciplinary care across critical conditions, which include stroke, cardiovascular disease, pulmonary, and oncology. "The Black Book survey stands apart by capturing what matters directly from the clinicians and administrators doing the work," said Chris Mansi, MD, CEO and co-founder of Viz.ai. "Being ranked the #1 Clinical AI platform is especially meaningful in the era of agentic AI, because clinical workflow is where value in healthcare is created. It's where agents act, and where they can directly improve patient outcomes, operational efficiency, and financial performance" Survey respondents rated Viz.ai highly across the capabilities most important to enterprise adoption, including: * Deep integration across imaging, EHR, and clinical systems * Scalability across service lines and care pathways * Speed to alert and time-to-treatment acceleration * Workflow orchestration and closed-loop communication * Overall enterprise value and long-term performance confidence This year's results reflect a broader shift in the market. According to Black Book, providers are increasingly rewarding solutions that deliver end-to-end clinical impact across the enterprise, delivering both clinical and financial value. Viz.ai's platform was consistently recognized for its ability to support the end-to-end workflow continuum, enabling agents to act where clinical work happens. About viz.ai. Viz.ai is the leader in building and deploying AI-powered Care Pathways and helping doctors do their work. The Viz Platform is deployed in 2,000 hospitals across the United States and trusted by many of the leading life sciences companies. The platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company to be awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai. Media contact. Caroline Rueve [email protected]

The Healthcare Technology Report
Mar 31st, 2026
Jieun Choe recognized among the Top Women Leaders in Healthcare Technology of 2025.

Jieun Choe recognized among the Top Women Leaders in Healthcare Technology of 2025. Published. March 31, 2026 At this year's NYC Awards Night, The Healthcare Technology Repo had the privilege of recognizing several leaders driving innovation in healthcare technology. Among them was Jieun Choe, COO of Viz.ai, who was recognized among the Top Women Leaders in Healthcare Technology of 2025. Jieun Choe is Chief Operating Officer at Viz.ai, where she leads the company's operations and growth across health systems. She is an enterprise leader and operator leading venture- and PE-backed growth-stage technology companies through scale, category definition, and operational maturity, with a proven ability to set vision, recruit and develop leadership talent, and translate product innovation into repeatable revenue and enterprise adoption. Viz.ai is a healthcare technology company that uses artificial intelligence to help care teams identify and coordinate treatment for patients with time-sensitive conditions. Its platform analyzes medical imaging and data in real time to support faster diagnosis and improve patient outcomes across areas such as stroke, cardiology, and other acute conditions. It was a pleasure having Jieun join The Healthcare Technology Repo in New York at this year's event. Picture: Jieun Choe at NYC Awards Night.

Fierce Healthcare
Mar 26th, 2026
Healthcare systems can create AI care pathways with new Viz.ai tool.

Healthcare systems can create AI care pathways with new Viz.ai tool. Artificial intelligence disease detection and care coordination platform Viz.ai has launched the first agentic platform for health systems to build and deploy their own customizable care pathways. The newly announced Viz Agent Studio will allow systems to create AI pathways within the Viz platform. The tool allows healthcare organizations to translate clinical guidelines into workflows, then deploy and scale them "across the enterprise using natural language," executives said. "This model of an AI care pathway at scale is very powerful," Viz.ai CEO and co-founder Chris Mansi, M.D., told Fierce Healthcare. "If you reduce variation to guideline-based care, outcomes improve dramatically," Mansi said. Improved clinical and financial outcomes from such pathways have been observed in multiple conditions, according to Mansi, from reducing length of stay by three days in stroke conditions and lowering readmissions in chronic obstructive pulmonary disease (COPD). "Agentic AI is obviously the future of every industry," Mansi said. "But in healthcare, it's so needed because today, so few patients are treated by guidelines." Research has shown that clinical practice guidelines are not always routinely followed. While drivers vary, a 2022 study, in particular, found primary care clinicians need 26.7 hours per day to follow national recommended guidelines for preventive care. The new tool from Viz.ai looks to change that. Healthcare professionals can speak or type into Viz Agent Studio to specify a condition and potential testing or treatments, according to Mansi. The AI will then run through clinical guidelines to create a customizable care pathway. "Once they build the pathway, we have an internal validation and verification step before we then essentially work with the hospital to launch it with their IT system," Mansi said. Viz Agent Studio is available to health systems using the Viz platform, according to Mansi. Camden, N.J.-based Cooper University Health Care is one health system using the new capabilities. Co-CEO of Cooper University Health Care Anthony Mazzarelli, M.D., said in a statement that clinical standardization has "always been one of the hardest problems to solve in medicine." "We've had the guidelines and the evidence," Mazzarelli said. "What's been missing is a reliable way to embed those standards into everyday workflows. Viz Agent Studio has the potential to help change that." Mansi said Viz.ai has been focused on improving clinician workflow since the company launched in 2016. Viz.ai's stroke detection tool was approved by the FDA in 2018. Since then, its platform has been deployed at 2,000 hospitals across the U.S., a scale that Mansi said covers "two-thirds" of the country's population. "It's never just been a tool for neurosurgeons or radiologists, it's for the entire patient journey," Mansi said. "It's always been truly agentic." Let Google know we are your trusted source. Add our editorial as a preferred source in your search results.

INACTIVE